• 1-hyper-sepsis.png
  • 2-abs-system.png
  • 3-icu-640x325.jpg

Over the years, Cascade Metrix has developed multiple technologies for glucose sensing and automated blood sampling. The picture below gives a snapshot of the various technologies developed and prototyped by CM, starting with mid infrared quantum cascade laser spectroscopy based glucose sensors to a version that uses electrochemical sensors from BST Bio Sensor Technology, GmbH

cm prod hx

CMX's transition from infrared spectroscopy to electrochemistry based sensing was described in a research article published with the Journal of Diabetes Science and TechnologyThese products illustrate a transition marked by a shift from a technology-centric focus in the early days to a much more user-centric philosophy, with each iteration becoming more accurate, safe, practical, reliable and cost-effective, culminating in the current embodiment. With the current alpha prototype, bench studies using spiked blood glucose samples and live animal-connected studies have been carried out. 

CM's technology platform is first being applied to the automated measurement of blood glucose in hospitalized patients to support tight glycemic control. The system performs automated/on-demand blood glucose monitoring in a safe, efficient and cost effective manner. The Automated Glucose Monitoring System (AGMS) is comprised of: 

  1. An Instrument Module, that consists of a pump, a pinch valve, circuitry and a touch screen tablet to control the device as well as display the glucose readings; and
  2. A Disposable Kit (life of ≥ 3-days), that consists of patient-dedicated micro-bore tubing, a specialized zero-dead volume luer adapter, an electrochemical flow-through glucose sensor, and saline based fluid bags for flushing and calibration. 


Fig 1: AGMS Prototype

Operation: Following an automated priming routine, the microbore tubing is connected to a conventional catheter (which could be a Peripheral IV, PICC, Central Venous, or Arterial). At the touch of a button, the system automatically calibrates the sensor, pulls blood (~ 0.5 ml) across the sensor for glucose measurement, and then re-infuses all of the blood safely back into the patient. Not a single drop of blood is wasted. Each automated measurement cycle (of calibration, sampling/measurement and reinfusion) takes about a minute and the cycle is repeated at clinician-defined intervals. Between each measurement, the system performs a slow saline infusion into the subject to keep the lines open.  

Through the user interface, audible and visual alarms are set and trends are continuously displayed or instantly recalled. All measurement data can also be uploaded to the hospital’s electronic medical record system. A fully functional prototype device is shown. 

Performance Validation: The CM system uses the same conventional electrochemical glucose sensor technology that is proven as safe, effective, and accurate in multiple products used in the hospitals for manual blood glucose testing. In in-vitro unprocessed whole blood studies, the system has demonstrated accuracy on par with lab analyzers. The system performance has also been demonstrated in pig and rodent models by tethering to a central catheter over an 8 hour period. Additional longer term preclinical studies are currently underway to support a US FDA Investigational Device Exemption (IDE) application. 

CM expects to obtain EU CE mark first to launch in select geographies. An FDA 510k application supported with trials in US hospitals is expected to be filed thereafter. 

CAUTION: Investigational device, limited by federal law to investigational use. 



Cascade Metrix (CM) is a medical device firm which has developed a proprietary system for automated blood sampling and analysis to support unmet needs in hospital-based point of care testing. CM has integrated glucose and lactate sensors from BST Biosensor Technologies, GmbH (leaders in reusable biosensor technologies). The company’s foremost product is an automated blood glucose monitoring system (AGMS) that is required to enable tight glycemic control in critical care settings thereby improving patient outcomes and reducing costs.


Frank Lloyd, Jr, M.D. MBA is the Co-founder and President of Cascade Metrix. He is leading the clinical operations of Cascade, in addition to helping raise private investments. He has led clinical research and development through his association with industry and academia for more than 20 years. He has also held appointments as a Clinical Associate Professor in Surgery at the Indiana University School of Medicine, President of the Center of Surgical Sciences and Trauma, and Medical Director of Methodist Research Institute. Dr. Lloyd graduated from IU School of Medicine, followed by a residency in general surgery from Howard University (Washington DC), and a fellowship in surgical oncology from Roswell Park Memorial Hospital (Buffalo, NY). He also completed the physician MBA program from IU's Kelley School of Business. He has been elected twice as the Coroner of Marion County, Indianapolis.


Kislaya Kunjan, PhD, MBA is the Co-founder and Chief Technology Officer of Cascade Metrix. He is the lead inventor of the product technology and is managing the company's product and business development aspects in collaboration with its partners and strategic investors alike. He holds an M.S. in Mechanical Engineering from Purdue (West Lafayette, IN) and an MBA from Cornell University (Ithaca, NY). While at Purdue, he designed and developed a novel infrared glucose sensing system under the mentorship of Prof. Jay Gore. His prior professional experience spans sales engineering with Saint-Gobain, medical device development with Vista  Biosciences and most recently a product management role with Johnson & Johnson/LifeScan. He completed his PhD in Health Informatics from the Indiana University School of Informatics and Computing (Indianapolis, IN).


David T. Giddings is a Co-Founder and serves as Chief Business Officer (CBO) of Cascade Metrix. His business career has been focused on healthcare, information technology, and life sciences businesses with both established and emerging publicly & privately held companies. He was with Eastman Kodak in General Management positions in Kodak's commercial Imaging and Information Systems and Healthcare Groups. Mr. Giddings joined Boehringer Mannheim Corporation in 1991 as VP and General Manager of their diagnostics Division and subsequently became President and COO of the company. He was appointed Chairman, President, and CEO of Diametrics Medical in 1995, a NASDAQ traded company, where he served for 6 years. Mr. Giddings served as  Digilab Inc’s President & CEO until July, 2009, and remains an active shareholder in the company.



Peter T. Kissinger, Ph.D., is the founder of Bioanalytical Systems, Inc., (NASDAQ BASI) - a life science contract research firm, which he led from 1974-2007, and is Professor of Bioanalytical Chemistry at Purdue University. Dr. Kissinger has published more than 230 scientific papers and is a Fellow of the American Association of Pharmaceutical Scientists and the American Association for the Advancement of Science. In 2005, he became the Chairman of Prosolia, which markets mass spectrometry innovations for life science, industrial and homeland security applications. In 2007, he and Candice Kissinger founded Phlebotics, Inc., a medical device company focused on diagnostic information for intensive care me.


Cascade Metrix, LLC.
11650 Olio Road, Suite 1000-110
Fishers, IN 46037 USA

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cascade Metrix has innovated upon an automated blood sampling system and analytical platform ("AutoSampler") that is designed to enable increased adoption of multiple POC medical diagnostic applications currently constrained by workflow challenges stemming from manual blood sampling methods. To obtain a rapid blood analysis, a specimen is either rushed to a laboratory for an in vitro “stat” determination or it is tested at the “point-of care” with a portable analyzer or hand-held device. CM will soon introduce a revolutionary ex-vivo blood analysis system. The AutoSampler automatically samples micro-liter quantities of whole blood from a patient and performs frequent measurements of various blood constituents without wasting a single drop of blood. The CM system introduces a whole new paradigm in patient monitoring that will both optimize nursing efficiency and improve patient care. The platform is enabling the commercialization of multiple products.

CM's technology features the following:

  • Integrates a proprietary blood sampling methodology with a clinically proven electrochemical sensor system
  • Uses the latest in microfluidics and microelectronics, making the system both safe for the patient and intuitive to clinicians
  • Is designed to be as familiar to set-up and use as modern infusion devices, making the product easily adapt into any hospital environment
  • Displays measurement histories and trends and other data at a touch, all of which will interface with existing patient monitors/hospital information systems
  • Over time, the automated blood sampling platform will be utilized to develop a range of patient monitoring and control system

Product Pipeline

Multiple Blood Analytes: CM plans to add other time sensitive tests to the AutoSampler platform. Whole blood sensors to monitor sepsis, heparin therapy, blood gases, electrolytes and certain biomarkers will be integrated to the CM sampling platform. Combining leading edge innovations in micro-fluidics, electro-chemistry, and machine intelligence, CM has developed patentable inventions covering technologies, designs, and other relevant operational aspects.

Novel Micro-volume IV Extension Kits: This product will be a revenue Generator in the $1.5B IV Catheter Market. The extension kit lowers the blood loss per draw by an order of magnitude (from current 3-5ml to 0.3-0.5ml with proposed set). The extension kit consists of specialized zero dead volume snap-on luer, a self-sealing aseptic quick release mechanism that eliminates the need for manual pinch valves, smooth pressure-relieving external contours on the luer and quick release, and a small bore specialized kink resistant tubing with see-through fluidic components.

Technology Development History

Over the years, Cascade Metrix has developed multiple technologies for glucose sensing and automated blood sampling. The picture below gives a snapshot of the various technologies developed and prototyped by CM, starting with mid infrared quantum cascade laser spectroscopy based glucose sensors to a version that uses electrochemical sensors from BST Bio Sensor Technology, GmbH


CM's transition from infrared spectroscopy to electrochemistry based sensing was described in a research article published with the Journal of Diabetes Science and Technology

CAUTION: Investigational device, limited by federal law to investigational use.